🚨 STOCK TO WATCH 🚨
₹1,050–₹1,060 → ₹1,374 → ₹1,530 → ₹3,113 👀
A fast-growing integrated pharmaceutical player appearing on my Weekly R4 Breakout Scanner.
Innova Captab Ltd.
📌 Buy Zone: ₹1,050–₹1,060
📌 Breakout Zone: ₹1,060
🛑 Stop Loss: ₹710
🎯 Target 1: ₹1,374
🎯 Target 2: ₹1,530
🎯 Target 3: ₹3,113
Why Innova Captab?
💊 Integrated pharma platform: The company operates across CDMO and Branded Generics, covering research, development, manufacturing and market-facing pharma operations.
🌍 Strong CDMO franchise: CDMO revenue reached ₹1,133.35 Cr in FY26, growing 23.8% YoY, with 350+ customers across 60+ countries.
📈 Branded Generics acceleration: FY26 Branded Generics revenue reached ₹496.67 Cr, representing 51.4% YoY growth.
🏭 Capacity expansion: The company has manufacturing facilities across Baddi, Dehradun, Taloja and Kathua, with further investment in manufacturing and R&D capabilities.
🌐 Export opportunity: Exports contributed 31.3% of FY26 revenue, with presence across 60+ countries and growing access to regulated markets.
📊 Weekly Camarilla R4 Breakout Setup
Why It Caught My Attention
✅ Strong CDMO growth
✅ 51%+ Branded Generics growth
✅ 350+ global customers
✅ Expanding manufacturing capacity
✅ Growing international exposure
✅ Weekly R4 Momentum Breakout
⚠️ High Risk – High Reward Setup. Always follow strict stop-loss and disciplined position sizing.
📢 Disclaimer: This content is for educational purposes only and not investment advice. Please do your own due diligence before making any investment decisions.
Risk Defined. Reward Visible.
© 20K Microcap Investing | R4 Momentum Desk
#InnovaCaptab #PharmaStocks #CDMO #Pharmaceuticals #PharmaIndia #HealthcareStocks #StockMarketIndia #IndianStocks #StocksToWatch #R4Breakout #MomentumInvesting #20KMicrocap
₹1,050–₹1,060 → ₹1,374 → ₹1,530 → ₹3,113 👀
A fast-growing integrated pharmaceutical player appearing on my Weekly R4 Breakout Scanner.
Innova Captab Ltd.
📌 Buy Zone: ₹1,050–₹1,060
📌 Breakout Zone: ₹1,060
🛑 Stop Loss: ₹710
🎯 Target 1: ₹1,374
🎯 Target 2: ₹1,530
🎯 Target 3: ₹3,113
Why Innova Captab?
💊 Integrated pharma platform: The company operates across CDMO and Branded Generics, covering research, development, manufacturing and market-facing pharma operations.
🌍 Strong CDMO franchise: CDMO revenue reached ₹1,133.35 Cr in FY26, growing 23.8% YoY, with 350+ customers across 60+ countries.
📈 Branded Generics acceleration: FY26 Branded Generics revenue reached ₹496.67 Cr, representing 51.4% YoY growth.
🏭 Capacity expansion: The company has manufacturing facilities across Baddi, Dehradun, Taloja and Kathua, with further investment in manufacturing and R&D capabilities.
🌐 Export opportunity: Exports contributed 31.3% of FY26 revenue, with presence across 60+ countries and growing access to regulated markets.
📊 Weekly Camarilla R4 Breakout Setup
Why It Caught My Attention
✅ Strong CDMO growth
✅ 51%+ Branded Generics growth
✅ 350+ global customers
✅ Expanding manufacturing capacity
✅ Growing international exposure
✅ Weekly R4 Momentum Breakout
⚠️ High Risk – High Reward Setup. Always follow strict stop-loss and disciplined position sizing.
📢 Disclaimer: This content is for educational purposes only and not investment advice. Please do your own due diligence before making any investment decisions.
Risk Defined. Reward Visible.
© 20K Microcap Investing | R4 Momentum Desk
#InnovaCaptab #PharmaStocks #CDMO #Pharmaceuticals #PharmaIndia #HealthcareStocks #StockMarketIndia #IndianStocks #StocksToWatch #R4Breakout #MomentumInvesting #20KMicrocap
Wyłączenie odpowiedzialności
Informacje i publikacje nie stanowią i nie powinny być traktowane jako porady finansowe, inwestycyjne, tradingowe ani jakiekolwiek inne rekomendacje dostarczane lub zatwierdzone przez TradingView. Więcej informacji znajduje się w Warunkach użytkowania.
Wyłączenie odpowiedzialności
Informacje i publikacje nie stanowią i nie powinny być traktowane jako porady finansowe, inwestycyjne, tradingowe ani jakiekolwiek inne rekomendacje dostarczane lub zatwierdzone przez TradingView. Więcej informacji znajduje się w Warunkach użytkowania.